Skip to content

GESTIPHARMA

Active Public limited companyfounded 1983active for 42 yearsRue de Montreuil sous Bois (H.) 15, 7022 MonsKBO/BCE: BE 0425.530.684

Lifetime

20 annual accounts with figures on one time axis, 42 filings since 1984
peak of €230,159 in 2025
€230,159▲ 58.7%
lowest -€120,626 in 2012
€77,529▲ €118,099
peak of €1.0m in 2018
€815,663▲ 10.5%
€43,758▲ 46.6%
peak of 1 FTE in 2019
-not published
Board2 names since 2013
2 directors and 1 other
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Gross margin from €144,990 to €230,159Profit of €77,529, after a lossDebts from €29,851 to €43,758Cash from €244,073 to €409,067

Key points

from the 2025 annual accounts

Result

€77,529 €77,529
-€40,6002024€77,5002025

Back in profit in 2025, after a loss of €40,570 in 2024.

Staff

1 employees on 31-12-2025
222024112025

In 2025, 1 employee joined and 1 left.

Filings

42 annual accounts since 1984
AprilJune31 JulyOctober199520102025

Six of the last ten came late. The 2019 accounts came in latest, 25 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,390 companies had the same profile as GESTIPHARMA has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,390 companies, not a prediction for GESTIPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director
Director, , since 25-11-2022
  • 59,612 sharesdeed of 18-07-2016
  • 250 sharesdeed of 18-07-2016

Shares in 1 company,

Board & ownership

Recent changes

(director) and (managing director) reappointed Discharge granted to · General meeting of 03-06-2024 · Gazette deed
1 director appointed, 2 resignations, 1 reappointment reappointed as managing director · appointed as director · and act as permanent representatives · General meeting of 25-11-2022 · Gazette deed
3 directors reappointed (managing director), and · General meeting of 09-06-2019 · Gazette deed
Company renamed from LUXIMMO to GESTIPHARMA Capital increase of €800,000 to €1,483,979.65 · The capital rose from €683,979.65 to €1,483,979.65, with 32,271 new shares · holds 59,612 shares · General meeting of 25-04-2016 · Gazette deed
All 62 events

Comparable companies

same main activity, similar in size and age
Company
GESTIPHARMA Mons €859,421 €230,159 94.9% -
ART GRAPHICS Destelbergen €844,246 €247,166 70.6% -
NACHRIS Izegem €860,106 €242,066 67.9% -
Xelyo Antwerp €781,069 €267,413 72.2% -
SUPPLY AND SUPPORT SERVICES Wezembeek-Oppem €936,308 €204,832 40.1% -
VEVADA Oosterzele €749,886 €214,423 60.3% -
EMHU Nazareth-De Pinte €969,330 €194,102 47.7% -

These companies have the same main activity as GESTIPHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €750,000 and €969,000, founded between 1985 and 1988.

Official details

Source: KBO
Status
Active since 31-12-1983Normal situation
Activity
Business and other management consultancyNACE 70200
Establishment unit
2.024.258.6537080 Frameries, since 01-01-1984
Financial year end
31 December
Peppol
Reachable via Peppol
Company details

Annual accounts 2025

≈ €380,000estimated
€859,421▲ 11.9%
Employeeson 31-12-2025
1=
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on GESTIPHARMA

GESTIPHARMA files the micro format. That format states no turnover. The gross margin rose from -€2,906 in 2006 to €230,159 in 2025.

The balance sheet grew most from 2012 to 2014 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about GESTIPHARMA

What is the company number of GESTIPHARMA?
The company number of GESTIPHARMA is 0425.530.684. The VAT number is the same number with BE in front: BE 0425.530.684.
Where is GESTIPHARMA based?
The registered office is at Rue de Montreuil sous Bois (H.) 15, 7022 Mons.Company details
What does GESTIPHARMA do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of GESTIPHARMA?
GESTIPHARMA is a public limited company (NV).
When was GESTIPHARMA founded?
GESTIPHARMA was founded on 31-12-1983.
Is GESTIPHARMA still active?
Yes, GESTIPHARMA is an active enterprise in the KBO register.
How many employees does GESTIPHARMA have?
GESTIPHARMA had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of GESTIPHARMA?
The turnover in financial year 2025 is about €380,000. This figure is estimated from the gross margin of €230,159 and 123 comparable companies (NACE 70200). It probably lies between €330,000 and €440,000.
Is GESTIPHARMA profitable?
In financial year 2025, GESTIPHARMA made a profit of €77,529.
Where can I find the annual accounts of GESTIPHARMA?
GESTIPHARMA filed 42 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of GESTIPHARMA due?
GESTIPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.